Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
As one of the major therapeutic options for cancer treatment, chemotherapy has limited selectivity against cancer cells. Consequently, this therapeutic strategy offers a small therapeutic window with potentially high toxicity and thus limited efficacy of doses that can be tolerated by patients. Anti...
Saved in:
Main Authors: | Rotimi Sheyi (Author), Beatriz G. de la Torre (Author), Fernando Albericio (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody-drug conjugates: Recent advances in linker chemistry
by: Zheng Su, et al.
Published: (2021) -
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
by: Louise Conilh, et al.
Published: (2021) -
Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance
by: Nick Evans, et al.
Published: (2022) -
Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy
by: Audrey Nathania Johan, et al.
Published: (2022) -
Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency
by: Dian Su, et al.
Published: (2021)